Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Overview | Financials
Company Name | Werewolf Therapeutics, Inc. |
Symbol | HOWL |
Currency | USD |
Price | 1.44 |
Market Cap | 64,171,008 |
Dividend Yield | 0% |
52-week-range | 1.38 - 8.194 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Daniel J. Hicklin Ph.D. |
Website | https://werewolftx.com |
An error occurred while fetching data.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD